Baxter International Inc. - 10-Q Summary (Q3 2006)
Business Context and Reporting Period
This filing covers the quarterly period ended September 30, 2006. Baxter International Inc. operates in three primary segments: Medication Delivery, BioScience, and Renal. The company is a large accelerated filer incorporated in Delaware. As of October 31, 2006, there were 654,456,738 shares of common stock outstanding.
Key Financial Metrics
| Metric (in millions) | Q3 2006 | Q3 2005 | 9M 2006 | 9M 2005 |
|---|---|---|---|---|
| Net Sales | $2,557 | $2,398 | $7,615 | $7,358 |
| Net Income | $374 | $116 | $965 | $664 |
| Diluted EPS | $0.57 | $0.18 | $1.47 | $1.06 |
| Gross Margin | 47.5% | 42.1% | 44.9% | 41.0% |
| Operating Cash Flow (9M) | $1,314 (2006) vs $1,421 (2005) | |||
| Cash & Equivalents | $2,067 (Sep 30, 2006) | |||
| Total Debt (Short + Long Term) | $2,808 (Sep 30, 2006) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 7% in Q3 and 3% for the nine months ended September 30, 2006, compared to the prior year. BioScience sales drove growth (up 15% in Q3), while Medication Delivery sales declined slightly (down 1% in Q3) due to the continued hold on COLLEAGUE pump shipments in the U.S.
- Profitability: Net income surged 222% in Q3 and 45% for the nine-month period. This was driven by improved gross margins (up 5.4 percentage points in Q3), lower net interest expense, and a significantly lower effective tax rate (21.9% in Q3 2006 vs. 66.9% in Q3 2005).
- Accounting Changes: The company adopted SFAS No. 123-R (Share-Based Payment) on January 1, 2006, resulting in an incremental stock compensation expense of $25 million in Q3 and $56 million for the nine months.
- Debt Management: Net interest expense decreased significantly due to lower average debt levels and higher cash balances. In August 2006, the company issued $600 million of term debt.
Guidance, Outlook, Risks, and Unusual Items
- COLLEAGUE Pump Matter: The company continues to hold shipments of COLLEAGUE infusion pumps in the United States. A Consent Decree with the U.S. government requires FDA approval of a corrective action plan before sales can resume. Significant charges ($94 million in the first nine months of 2006) were recorded for remediation costs.
- Divestiture: On October 2, 2006 (subsequent to the reporting period), Baxter entered an agreement to sell its Transfusion Therapies business to an affiliate of Texas Pacific Group for $540 million. The sale is expected to close in Q1 2007.
- Legal Contingencies: The company faces ongoing litigation regarding mammary implants, plasma-based therapies (HIV/Hepatitis C claims), and vaccine-related claims. While reserves are established, outcomes remain uncertain.
- Outlook: Management expects continued growth in BioScience products (ADVATE, IVIG) and Renal products. The Medication Delivery segment remains impacted by the U.S. pump hold and generic competition.
Investor Verification Checklist
- COLLEAGUE Pump Resolution: Verify the status of the FDA corrective action plan and the timeline for resuming U.S. sales of COLLEAGUE pumps.
- Transfusion Therapies Sale: Confirm the closing date and final proceeds of the $540 million sale to Texas Pacific Group.
- Stock Compensation Impact: Assess the long-term impact of SFAS No. 123-R adoption on future earnings and cash flow.
- Legal Reserves: Review updates on mammary implant and plasma-based therapy litigation to ensure reserves remain adequate.
- Debt Maturities: Monitor the company's ability to manage debt maturities and maintain liquidity given the recent $600 million issuance and ongoing debt paydowns.